Noisy
← this week  ·  Subscribe →

The world is being quietly rearranged by people who write very long documents.

Federal Register · March 30, 2026
The title they went with Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests Noisy translates that to

FDA finally loosens approval rules for TB tests, fifteen years after first trying

The regulatory category requiring the most stringent evidence before market entry is, in this case, the thing that slowed access to better diagnostics for a disease with abundant evidence and over a million deaths a year. The caution was the problem.
What happened
US health regulators are proposing to move certain tuberculosis infection tests from a high-risk category requiring extensive review to a lower-risk category. This means these tests will need less rigorous approval processes, making them easier and faster to bring to market.
Why it matters
For decades, new diagnostic tests for tuberculosis have faced a slow and expensive approval process. This change allows for new types of tests to be evaluated using updated standards. It could speed up the availability of better diagnostic tools, especially for infections that are hard to detect.
The signal
Manufacturers who parked TB diagnostic development because the full premarket approval cost made the market math not work can now revisit those decisions. Expect development programs to restart and new 510(k) submissions to follow, probably within two to three years of finalization.
If you insist
Read the original →
The Sendoff
The advisory panel voted unanimously in 2023 that reclassification was appropriate. The proposed rule arrived in March 2026. The comment period is now open.